Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome

被引：6
|
作者：
Frater, J
Dunn, D
Weber, JN
McClure, MO
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Div Med, Wright Fleming Inst, Jefferiss Res Labs, London W2 1PG, England
[2] MRC, HIV Clin Trials Unit, London, England
来源：
JOURNAL OF INFECTIOUS DISEASES | 2002年 / 185卷 / 09期
关键词：
D O I：
10.1086/340127
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1376 / 1376
页数：1
相关论文
共 50 条
  • [41] Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness
    Capel, Elena
    Martrus, Gloria
    Parera, Mariona
    Clotet, Bonaventura
    Angel Martinez, Miguel
    JOURNAL OF GENERAL VIROLOGY, 2012, 93 : 2625 - 2634
  • [42] Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1
    Sutherland, Katherine A.
    Mbisa, Jean L.
    Cane, Patricia A.
    Pillay, Deenan
    Parry, Chris M.
    JOURNAL OF GENERAL VIROLOGY, 2014, 95 : 190 - 200
  • [43] Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations
    Gonzalez, LMF
    Aguiar, RS
    Afonso, A
    Brindeiro, PA
    Arruda, MB
    Soares, MA
    Brindeiro, RM
    Tanuri, A
    JOURNAL OF GENERAL VIROLOGY, 2006, 87 : 1303 - 1309
  • [44] Association of RNA helicase a with human immunodeficiency virus type 1 particles
    Roy, BB
    Hu, J
    Guo, XF
    Russell, RS
    Guo, F
    Kleiman, L
    Liang, C
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (18) : 12625 - 12635
  • [45] Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations - Reply
    Young, B
    Kuritzkes, DR
    JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02): : 570 - 571
  • [46] Protease inhibitors: A therapeutic breakthrough for the treatment of patients with human immunodeficiency virus
    Lewis, JS
    Terriff, CM
    Coulston, DR
    Garrison, MW
    CLINICAL THERAPEUTICS, 1997, 19 (02) : 187 - 214
  • [47] Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir
    Côté, HCF
    Brumme, ZL
    Harrigan, PR
    JOURNAL OF VIROLOGY, 2001, 75 (02) : 589 - 594
  • [48] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE
    TYAGI, SC
    BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1992, 70 (05): : 309 - 315
  • [49] Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742
    Dekhtyar, Tatyana
    Ng, Teresa I.
    Lu, Liangjun
    Masse, Sherie
    DeGoey, David A.
    Flosi, William J.
    Grampovnik, David J.
    Klein, Larry L.
    Kempf, Dale J.
    Molla, Akhteruzzarnan
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) : 1337 - 1344
  • [50] NONVIRAL CELLULAR SUBSTRATES FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE
    SHOEMAN, RL
    KESSELMEIER, C
    MOTHES, E
    HONER, B
    TRAUB, P
    FEBS LETTERS, 1991, 278 (02) : 199 - 203
12345